[Federal Register Volume 88, Number 7 (Wednesday, January 11, 2023)]
[Notices]
[Pages 1599-1600]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-00390]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2018-N-3091]


Advisory Committee; Cardiovascular and Renal Drugs Advisory 
Committee; Renewal; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration is correcting a notice 
entitled ``Advisory Committee; Cardiovascular and Renal Drugs Advisory 
Committee; Renewal'' that appeared in the Federal Register of December 
13, 2022. The document announced the renewal of the

[[Page 1600]]

Cardiovascular and Renal Drugs Advisory Committee. The document was 
published with the incorrect docket number. This document corrects that 
error.

FOR FURTHER INFORMATION CONTACT: Lisa Granger, Office of Policy, 
Planning, Legislation and International Affairs, Food and Drug 
Administration, 301-796-9115, [email protected].

SUPPLEMENTARY INFORMATION: In the Federal Register of Tuesday, December 
13, 2022 (87 FR 76197), in FR Doc. 2022-27014, on page 76197 the 
following correction is made:
    1. On page 76197, in the first column of the header of the 
document, ``Docket No. FDA-2022-N-3091'' is corrected to read ``Docket 
No. FDA-2018-N-3091''.

    Dated: January 3, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-00390 Filed 1-10-23; 8:45 am]
BILLING CODE 4164-01-P


